ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The later, originally developed to inhibit BCR-ABL in Chronic Myeloid Leukemia (CML), could also inhibit c-KIT, the receptor for stem cell factor, thereby inducing apoptosis of mast cells, including synovial mast cells involved in inflammatory pathways [5].